Patients who receive doxorubicin. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy5

Cell Line, Tumor Tumor Cells, Cultured Heart Myocardium Eyelids

Organisms1

Diseases17

Breast Neoplasms Leukemia P388 Sarcoma Cardiomyopathies Heart Diseases Osteosarcoma Ovarian Neoplasms Bone Neoplasms Soft Tissue Neoplasms Lung Neoplasms Leukopenia Neutropenia Lymphoma, Non-Hodgkin Neoplasms Lymphoma, Large B-Cell, Diffuse Hodgkin Disease Carcinoma, Small Cell

Chemicals and Drugs41

Doxorubicin Antibiotics, Antineoplastic Vincristine Razoxane Cyclophosphamide Antineoplastic Agents Drug Carriers Liposomes P-Glycoprotein Prednisone Etoposide Polyethylene Glycols Paclitaxel Vinblastine Cisplatin Daunorubicin Cardiotoxins Hydroxyethylrutoside Ifosfamide Anthracyclines Bleomycin Mitoxantrone Methotrexate Verapamil Fluorouracil Antineoplastic Agents, Phytogenic Taxoids DNA Topoisomerases, Type II Naphthacenes Procarbazine Prodrugs Nanocapsules Epirubicin Aclarubicin Topoisomerase II Inhibitors Multidrug Resistance-Associated Proteins Dacarbazine Cyclosporins Mechlorethamine Antibodies, Monoclonal, Murine-Derived Granulocyte Colony-Stimulating Factor

Analytical, Diagnostic and Therapeutic Techniques and Equipment18

Antineoplastic Combined Chemotherapy Protocols Drug Carriers Drug Administration Schedule Treatment Outcome Combined Modality Therapy Drug Delivery Systems Drug Screening Assays, Antitumor Disease-Free Survival Survival Analysis Infusions, Intravenous Chemotherapy, Adjuvant Nanocapsules Survival Rate Xenograft Model Antitumor Assays Neoplasm Transplantation Remission Induction Inhibitory Concentration 50 Neoplasm Staging

Phenomena and Processes12

Drug Resistance, Neoplasm Drug Resistance, Multiple Dose-Response Relationship, Drug Drug Synergism Apoptosis Drug Resistance Cell Survival Time Factors Genes, MDR Inhibitory Concentration 50 Tissue Distribution DNA Damage

Technology, Industry, Agriculture4

Liposomes Polyethylene Glycols Nanocapsules Nanoparticles

Information Science1

Health Care4

Treatment Outcome Disease-Free Survival Survival Analysis Survival Rate

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Technology, Industry, Agriculture Information Science Health Care

Doxorubicin Antibiotics, Antineoplastic Vincristine Antineoplastic Combined Chemotherapy Protocols Razoxane Cyclophosphamide Antineoplastic Agents Drug Resistance, Neoplasm Drug Carriers Liposomes P-Glycoprotein Drug Resistance, Multiple Prednisone Breast Neoplasms Cell Line, Tumor Etoposide Polyethylene Glycols Paclitaxel Vinblastine Cisplatin Daunorubicin Drug Administration Schedule Dose-Response Relationship, Drug Leukemia P388 Cardiotoxins Hydroxyethylrutoside Drug Synergism Ifosfamide Apoptosis Treatment Outcome Sarcoma Tumor Cells, Cultured Combined Modality Therapy Anthracyclines Bleomycin Drug Delivery Systems Drug Resistance Cell Survival Drug Screening Assays, Antitumor Mitoxantrone Methotrexate Disease-Free Survival Survival Analysis Infusions, Intravenous Cardiomyopathies Heart Diseases Verapamil Heart Osteosarcoma Fluorouracil Antineoplastic Agents, Phytogenic Taxoids DNA Topoisomerases, Type II Mice, Nude Chemotherapy, Adjuvant Naphthacenes Procarbazine Prodrugs Nanocapsules Epirubicin Survival Rate Aclarubicin Ovarian Neoplasms Xenograft Model Antitumor Assays Bone Neoplasms Soft Tissue Neoplasms Neoplasm Transplantation Lung Neoplasms Leukopenia Topoisomerase II Inhibitors Time Factors Remission Induction Genes, MDR Multidrug Resistance-Associated Proteins Neutropenia Dacarbazine Cyclosporins Lymphoma, Non-Hodgkin Neoplasms Inhibitory Concentration 50 Mechlorethamine Lymphoma, Large B-Cell, Diffuse Antibodies, Monoclonal, Murine-Derived Granulocyte Colony-Stimulating Factor Myocardium Tissue Distribution Neoplasm Staging Hodgkin Disease Eyelids Nanoparticles DNA Damage Carcinoma, Small Cell

No FAQ available that match "patients who receive doxorubicin"